No. of isolates and % prevalence relative to the total (n) | Statistical significance of prevalence P value** | ||||
---|---|---|---|---|---|
Genetic profile | APEC (n = 21) | NMEC (n = 15) | septicemic /UPEC (n = 23) | APEC vs human ExPEC | septicemic/UPEC vs NMEC |
Phylogroup: B2 D | 20 (95%) 1 (5%) | 6 (40%) 9 (60%) | 14 (61%) 9 (39%) | + (0,001) | - (0,177) |
fimH | 21 (100%) | 13 (87%) | 20 (87%) | - (0,065) | - (0,370) |
FimAv MT78 | 2 (10%) | 6 (40%) | 10 (43%) | + (0,007) | - (0,551) |
papC | 21 (100%) | 13 (87%) | 21 (91%) | - (0,162) | - (0,360) |
papGI | 0 | 1 | 1 | - (0,411) | - (0,491) |
papG II | 21 (100%) | 11 (73%) | 17 (74%) | + (0,008) | - (0,291) |
papG III | 0 | 0 | 0 | - | - |
sfa/focDE | 0 | 1 | 0 | - (0,644) | - (0,395) |
sfaS | 0 | 1 | 0 | - (0,644) | - (0,395) |
focG | 0 | 0 | 0 | - | - |
afa/draBC | 0 | 0 | 0 | - | - |
bmaE | 0 | 0 | 0 | - | - |
nfaE | 0 | 0 | 0 | - | - |
gafD | 0 | 0 | 0 | - | - |
cnf1 | 0 | 0 | 0 | - | - |
cdt | 0 | 1 | 0 | - (0,644) | - (0,395) |
sat | 0 | 10 (66%) | 11 (48%) | + (0,023) | - (0,141) |
tsh* | 7 (33%) | 1 (7%) | 2 (9%) | + (0,018) | - (0,660) |
hlyA | 0 | 3 (20%) | 3 (13%) | - (0,061) | - (0,292) |
iroN* | 21 (100%) | 5 (33%) | 10 (43%) | + (0,000) | - (0,390) |
fyuA | 20 (95%) | 15 (100%) | 23 (100%) | - (0,356) | - (1,000) |
iutA* | 20 (95%) | 13 (87%) | 20 (87%) | - (0,295) | - (0,370) |
neuC (K1) | 21 (100%) | 15 (100%) | 23 (100%) | - | - |
cvaC* | 13 (62%) | 3 (20%) | 6 (26%) | + (0,003) | - (0,490) |
iss* | 20 (95%) | 3 (20%) | 8 (35%) | + (0,000) | - (0,272) |
traT* | 20 (95%) | 12 (80%) | 20 (87%) | - (0,207) | - (0,292) |
malX | 20 (95%) | 14 (93%) | 23 (100%) | - (0,466) | - (0,395) |
ibeA | 2 (10%) | 2 (13%) | 1 (4%) | - (0,354) | - (0,286) |
usp | 20 (95%) | 14 (93%) | 23 (100%) | - (0,466) | - (0,395) |